American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers

Ca-A Cancer Journal for Clinicians

Volumn 51, Issue 1, 2001, Pages 38-75

  Smith, Robert A ^a   von Eschenbach, Andrew C ^b   Wender, Richard ^c   Levin, Bernard ^d   Byers, Tim ^e   Rothenberger, David ^f   Brooks, Durado ^a   Creasman, William ^g   Cohen, Carmel ^h   Runowicz, Carolyn ⁱ   Saslow, Debbie ^a   Cokkinides, Vilma ^a   Eyre, Harmon ^a  

^a AMERICAN CANCER SOCIETY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h MOUNT SINAI MEDICAL CENTER   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARIUM; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN;

ADULT; ANTIGEN DETECTION; ARTICLE; BARIUM ENEMA; BREAST EXAMINATION; CANCER CONTROL; CANCER RISK; CANCER SCREENING; CLINICAL PROTOCOL; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOUBLE CONTRAST RADIOGRAPHY; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; FEMALE; HUMAN; LUNG CANCER; MALE; MAMMOGRAPHY; MEDICAL SOCIETY; MEDICAL TECHNOLOGY; OCCULT BLOOD; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; SIGMOIDOSCOPY; SPUTUM CYTODIAGNOSIS; THORAX RADIOGRAPHY;

COLORECTAL NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; GUIDELINES; HUMANS; LUNG NEOPLASMS; MALE; PROSTATIC NEOPLASMS;

EID: 0035117342     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.51.1.38     Document Type: Article

References (182)

1. American Cancer Society guidelines for the early detection of cancer
2. American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: Update 1997
3. American Cancer Society guidelines for the early detection of breast cancer: Update 1997
4. Cancer statistics, 2001
5. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: Prostate and endometrial cancers
6. American Cancer Society guideline for the early detection of prostate cancer: Update 1997
7. Prostate carcinoma screening in the county of Tyrol, Austria: Experience and results
8. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates
9. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers
10. Interpreting recent trends in prostate cancer incidence and mortality
11. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota
12. The changing face of prostate cancer: Evidence for the effectiveness of prostate cancer screening
13. Screening for prostate cancer. The challenge of promoting informed decision making in the absence of definitive evidence of effectiveness
14. What should men know about prostate-specific antigen screening before giving informed consent?
15. The impact of informed consent on patient interest in prostate-specific antigen screening
16. Predictors of interest in prostate-specific antigen screening and the impact of informed consent: What should we tell our patients?
17. Screening for prostate cancer with the prostate-specific antigen test: Are patients making informed decisions?
18. Family history and risk of fatal prostate cancer
19. Status report on prostate cancer in African Americans: A national blueprint for action
20. Prevention of colorectal cancer by colonoscopic polypectomy: The national polyp study workgroup
21. Colorectal cancer screening: Clinical guidelines and rationale [published errata appear in Gastroenterology 1997 Mar;112:1060 and 1998 Mar;114:625]
22. ACS report on the cancer-related health checkup
23. Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods
24. Screening for colorectal cancer with the fecal occult blood test: A background paper. American College of Physicians
25. Use of colonoscopy to screen asymptomatic adults for colorectal cancer
26. Colorectal cancer prevention 2000: Screening recommendations of the American College of Gastroenterology
27. Cost-effectiveness of double-contrast barium enema in screening for colorectal cancer
28. Virtual colonoscopy
29. Molecular approaches for colorectal cancer screening
30. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel
31. Lessons from hereditary colorectal cancer
32. Clinical evidence for the adenoma-carcinoma sequence
33. Reducing mortality from colorectal cancer by screening for fecal occult blood
34. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer
35. Screening sigmoidoscopy and colorectal cancer mortality
36. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans
37. Screening endoscopy and risk of colorectal cancer in United States men
38. Prostate cancer screening: What we know and what we need to know
39. Flexible sigmoidoscopy as a mass screening tool
40. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy
41. Risk of colorectal cancer in the families of patients with adenomatous polyps: National polyp study workgroup
42. Colon cancer screening
43. Varying features of early age-of-onset "sporadic" and hereditary nonpolyposis colorectal cancer patients
44. Randomised study of screening for colorectal cancer with faecal-occult- blood test
45. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
46. Colorectal cancer mortality: Effectiveness of biennial screening for fecal occult blood
47. Fecal occult blood screening for colorectal cancer: Is mortality reduced by chance selection for screening colonoscopy?
48. Fecal occult blood screening in the Minnesota study: Role of chance detection of lesions
49. Screening for colorectal cancer - United States, 1997
50. Summary report to the American Cancer Society: Colorectal cancer screening teleconferences with managed care medical directors
51. Organizational systems used by California capitated medical groups and independent practice associations to increase cancer screening
52. Suggested technique for fecal occult blood testing and interpretation in colorectal cancer screening
53. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy
54. Videotape-based decision aid for colon cancer screening. A randomized, controlled trial
55. Participation in colorectal cancer screening: A review
56. Detection of colorectal polyps with CT colography: Initial assessment of sensitivity and specificity
57. Virtual colonoscopy
58. Molecular stool screening for colorectal cancer. Using DNA markers may be beneficial, but large scale evaluation is needed
59. Early detection of prostate cancer following repeated examinations by multiple modalities: Results of the American Cancer Society National Prostate Cancer Detection Project
60. Endometrial cancer
61. Endometrial sampling techniques in the diagnosis of abnormal uterine bleeding
62. Mass screening for endometrial cancer directed in risk groups of patients with diabetes and patients with hypertension
63. Measuring the thickness - Is that all we have to do for sonographic assessment of endometrium in postmenopausal women?
64. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: A prospective long-term study using transvaginal ultrasound
65. Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen
66. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening
67. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: A prospective study using office endometrial biopsy
68. Gynecologic surveillance of women on tamoxifen: First do no harm
69. Significance of endometrial cells in the detection of endometrial carcinoma and its precursors
70. Significance of endometrial cells in cervicovaginal smears
71. Risk factors for endometrial cancer at different ages
72. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues
73. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
74. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women
75. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement
76. Use of oral contraceptives and endometrial cancer risk
77. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial carcinoma
78. Risk of endometrial cancer following estrogen replacement with and without progestins
79. Reproductive, menstrual, and medical risk factors for endometrial cancer: Results from a case-control study
80. Reproductive factors and risk of endometrial cancer
81. Menstruation span-a time-limited risk factor for endometrial carcinoma
82. A case-control study of endometrial cancer in relation to reproductive, somatometric, and life-style variables
83. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
84. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
85. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer
86. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers
87. Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer
88. The Christie Hospital adjuvant tamoxifen trial
89. Risk of endometrial cancer after tamoxifen treatment of breast cancer
90. Tamoxifen therapy for breast cancer and endometrial cancer risk
91. The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma
92. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer
93. Endometrial cancer and age at last delivery: Evidence for an association
94. Is the risk of cancer of the corpus uteri reduced by a recent pregnancy? A prospective study of 765,756 Norwegian women
95. An evaluation of risk factors for endometrial hyperplasia in premenopausal women with abnormal menstrual bleeding
96. A case-control study on risk factors for uterine endometrial cancer in Japan
97. Childbearing at older age and endometrial cancer risk
98. Childbearing and mortality from cancer of the corpus uteri
99. Reproductive factors and risk of endometrial cancer
100. Role of reproductive factors on the risk of endometrial cancer
101. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico
102. Long-term impact of reproductive factors on cancer risk
103. Cancer risk after evaluation for infertility
104. Endometrial adenocarcinoma and the Stein-Leventhal syndrome
105. Endometrial adenocarcinoma and the polycystic ovary syndrome
106. Carcinoma of endometrium and polycystic ovaries in a 22-year-old patient
107. Chronic anovulation syndrome and associated neoplasia
108. Endometrial carcinoma; ovarian dysfunction - A risk factor in young women
109. Endometrial cancer, obesity, and body fat distribution
110. Association of incident carcinoma of the endometrium with body weight and fat distribution in older women: Early findings of the Iowa women's health study
111. Diet, body size, physical activity, and the risk of endometrial cancer
112. Body mass at different ages and subsequent endometrial cancer risk
113. Body mass index, weight gain, and risk of endometrial cancer
114. Diabetes, body size, and risk of endometrial cancer
115. Relation of endometrial cancer risk to past and contemporary body size and body fat distribution
116. Height and weight in relation to uterine corpus cancer morbidity and mortality. A follow-up study of 570,000 women in Norway
117. A case-control study of diabetes mellitus and cancer risk
118. Extracolonic cancer in hereditary nonpolyposis colorectal cancer
119. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer
120. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome
121. Cancer risk in mutation carriers of DNA-mismatch-repair genes
122. Detection of occult endometrial carcinoma
123. Diagnostic and therapeutic advances in gynecologic oncology: Screening for gynecologic cancer
124. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer
125. Hereditary nonpolyposis colorectal cancer (Lynch syndrome). An updated review
126. Prognostic factors in clinical stage I non-small cell lung cancer
127. Mediastinal lymph node dissection for lung cancer. The Memorial experience
128. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer
129. Lung cancer
130. Youth tobacco surveillance, 1998-1999
131. Smoking, smoking cessation, and lung cancer in the UK since 1950: Combination of national statistics with two case-control studies
132. Screening for lung cancer. A critique of the Mayo Lung Project
133. Lung cancer screening and the surgical oncologist: The controversy
134. Lung cancer detected during a screening program using four-month chest radiographs
135. Early lung cancer action project: Overall design and findings from baseline screening
136. The early identification of lung cancer by sputum cytology
137. Molecular risk assessment in current and former cigarette smokers
138. Screening for lung cancer
139. Early lung cancer detection
140. Varese meeting report
141. Reanalysis of the Mayo Lung Project data: The impact of confounding and effect modification
142. Ethics and consent
143. State- and sex-specific prevalence of selected characteristics - Behavioral risk factor surveillance system, 1996 and 1997
144. State-Specific prevalence of selected health behaviors, by race and ethnicity - Behavioral risk factor surveillance system, 1997
145. Primary care and receipt of preventive services
146. Missed cancer screening opportunities among older women: A provider survey
147. Trends in self-reported use of mammograms (1989-1997) and Papanicolaou tests (1991-1997) - Behavioral risk factor surveillance system
148. Knowledge, attitudes, and screening practices among older men regarding prostate cancer
149. Implementing recommendations for the early detection of breast and cervical cancer among low-income women
150. Cultural barriers to cancer screening among African American women: A critical review of the qualitative literature
151. Trends in mammography use and their relation to physician and other factors
152. The role of physician recommendation in women's mammography use: Is it a 2-stage process?
153. Mammography attitudes and usage study, 1992
154. Barriers to screening for breast cancer
155. Why do some women get regular mammograms?
156. Screening mammography: A missed clinical opportunity?
157. Chronic disease as a barrier to breast and cervical cancer screening
158. Current use and how to increase mammography screening in women
159. Cancer: Improving early detection and prevention. A community practice randomised trial
160. Changing office routines to enhance preventive care. The preventive GAPS approach
161. Characteristics of primary care office systems as predictors of mammography utilization
162. The effect of routine use of computer-generated preventive reminders in a clinical practice
163. Promoting cancer screening. A randomized, controlled trial of three interventions
164. Promoting cancer prevention activities by primary care physicians. Results of a randomized, controlled trial